REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02
|
RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
|
issued a press release providing clinical milestones for
DaxibotulinumtoxinA for Injection (RT002) and financial outlook
for 2017. The Company also announced its unaudited December 31,
2016 cash and investments balance. A copy of the press release is
furnished as Exhibit 99.1 to this report.
furnished as Exhibit 99.1 to this current report shall not be
deemed to be filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act of 1933, as amended. The information contained in
this Item 2.02 and in the press release furnished as Exhibit 99.1
to this current report shall not be incorporated by reference
into any filing with the U.S. Securities and Exchange Commission
made by the Company, whether made before or after the date
hereof, regardless of any general incorporation language in such
filing.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
|
Number
|
Description
|
|
|
99.1
|
Press Release dated January 5, 2017.
|
About REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC)
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation. REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Recent Trading Information
REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) closed its last trading session down -0.30 at 23.50 with 306,246 shares trading hands.
